Literature DB >> 31378882

MiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5.

C-M Sun1, G-M Zhang, H-N Qian, S-J Cheng, M Wang, M Liu, D Li.   

Abstract

OBJECTIVE: To elucidate the correlation between microRNA-1266 (miR-1266) and prostate cancer (PCa) progression, and to investigate the possible underlying mechanism. PATIENTS AND METHODS: The expression level of miR-1266 and protein arginine methyltransferase 5 (PRMT5) in PCa tissues and cell lines was first detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). After up-regulating or down-regulating miR-1266 expression in cells, cell proliferation, migration and invasion abilities were detected. Possible target genes of miR-1266 were predicted and validated by bioinformatics analysis and dual-luciferase reporter gene assay, respectively. Finally, abnormal expression of PRMT5 was ascertained after transfection.
RESULTS: MiR-1266 was lowly expressed in PCa tissues and cell lines, whereas PRMT5 exhibited the opposite results. Up-regulated expression of miR-1266 significantly inhibited the proliferation, migration and invasion abilities of PC-3 cells. However, the growth and migration of DU145 cells with low miR-1266 expression were significantly accelerated. Meanwhile, the number of invading cells was significantly increased. PRMT5 was verified as a potential target gene of miR-1266. Furthermore, results found that miR-1266 was negatively correlated with PRMT5. In addition, the expression of PRMT5 was remarkably decreased after miR-1266 overexpression, which could be restored after knockdown of miR-1266.
CONCLUSIONS: MiR-1266 inhibits the growth and metastasis of PCa by targeting PRMT5. We may provide a potential and prospective therapeutic target for PCa.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31378882     DOI: 10.26355/eurrev_201908_18525

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  Protein arginine methyltransferase 5: a potential cancer therapeutic target.

Authors:  Yuanyang Yuan; Hong Nie
Journal:  Cell Oncol (Dordr)       Date:  2021-01-19       Impact factor: 6.730

2.  microRNA-1266-5p directly targets DAB2IP to enhance oncogenicity and metastasis in oral cancer.

Authors:  Chih-Yu Peng; Che-Yi Lin; Szu-Han Chen; Yi-Wen Liao; Cheng-Chia Yu; Shiao-Pieng Lee
Journal:  J Dent Sci       Date:  2021-11-26       Impact factor: 3.719

Review 3.  MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy.

Authors:  Milad Ashrafizadeh; Hui Li Ang; Ebrahim Rahmani Moghadam; Shima Mohammadi; Vahideh Zarrin; Kiavash Hushmandi; Saeed Samarghandian; Ali Zarrabi; Masoud Najafi; Reza Mohammadinejad; Alan Prem Kumar
Journal:  Biomolecules       Date:  2020-07-12

Review 4.  Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.

Authors:  Deniz Mortazavi; Behnoush Sohrabi; Meysam Mosallaei; Ziba Nariman-Saleh-Fam; Milad Bastami; Yaser Mansoori; Abdolreza Daraei; Sepideh Zununi Vahed; Shadan Navid; Zahra Saadatian; Tannaz Jamialahmadi; Yong Teng; Amirhossein Sahebkar
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

5.  miR-1266-3p Suppresses Epithelial-Mesenchymal Transition in Colon Cancer by Targeting P4HA3.

Authors:  Hailang Zhou; Shu Huang; Changjiang Shao; Junwei Zou; Aijun Zhou; Jiufeng Yu; Chunfang Xu
Journal:  Anal Cell Pathol (Amst)       Date:  2022-04-07       Impact factor: 4.133

Review 6.  PRMT5 function and targeting in cancer.

Authors:  Hyungsoo Kim; Ze'ev A Ronai
Journal:  Cell Stress       Date:  2020-07-13

7.  PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.

Authors:  Yongshuai Jiang; Yuanyang Yuan; Ming Chen; Shengzhe Li; Jun Bai; Yuanteng Zhang; Ying Sun; Guojue Wang; Haiyan Xu; Ziyu Wang; Yingxia Zheng; Hong Nie
Journal:  Theranostics       Date:  2021-08-28       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.